NASDAQ:PBM Psyence Biomedical Q2 2025 Earnings Report $5.00 -0.09 (-1.67%) As of 12:46 PM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast Psyence Biomedical EPS ResultsActual EPS$25.40Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/APsyence Biomedical Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/APsyence Biomedical Announcement DetailsQuarterQ2 2025Date1/23/2025TimeBefore Market OpensConference Call DateN/AConference Call TimeN/AConference Call ResourcesEarnings HistoryCompany Profile Psyence Biomedical Earnings HeadlinesPsyence BioMed Sets U.S. Ibogaine Manufacturing Pathway With BenuviaOctober 5 at 12:28 PM | rttnews.comPsyence BioMed Partners with DEA-Registered Benuvia Operations to Establish U.S. Manufacture of Pharmaceutical-Grade IbogaineOctober 5 at 7:00 AM | globenewswire.comA weekly dividend fund holding Nvidia and PalantirCrowdStrike, Palantir, Nvidia none of them pay a real dividend. But one fund holding the biggest AI names distributes income every single Thursday, with payouts reported as high as $1,051 a month. Chief Income Strategist Tim Plaehn breaks down the fund's real Thursday distribution history, how the income is generated, and how to buy it in any brokerage account.October 6 at 1:00 AM | Investors Alley (Ad)Psyence Biomedical (NASDAQ:PBM) Stock Bumped Up to Hold by Wall Street ZenOctober 3 at 1:25 AM | americanbankingnews.comPsyence BioMed Stock Rises On Exclusive U.S. Ibogaine License DealSeptember 28, 2026 | rttnews.comPsyence BioMed Announces Exclusive U.S. Ibogaine Licence for Texas Ibogaine Research CorporationSeptember 28, 2026 | financialpost.comFSee More Psyence Biomedical Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Psyence Biomedical? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Psyence Biomedical and other key companies, straight to your email. Email Address About Psyence BiomedicalPsyence Biomedical (NASDAQ:PBM) (NASDAQ: PBM) is a clinical-stage biotechnology company focused on developing psychedelic-based therapeutics for mental health conditions. The company’s research centers on naturally derived psilocybin and its potential use in medically supervised treatment programs. Its lead development program is designed to evaluate psilocybin-assisted therapy for adjustment disorder in patients with cancer. Psyence Biomedical’s activities include drug development, clinical research and work with external partners to advance psychedelic medicines toward potential regulatory approval and commercialization. The company became publicly traded on Nasdaq in February 2024 following a business combination with Newcourt Acquisition Corp. Psyence Biomedical is part of the broader Psyence Group, which has pursued psychedelic medicine research and development internationally. As a clinical-stage company, its programs remain subject to clinical, regulatory and commercial uncertainties.View Psyence Biomedical ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles AI Chip Demand Gives Linde a New Growth Catalyst3 Low-Rated Stocks Analysts May Be Underestimating Ahead of Q3 EarningsNVIDIA’s Record High Raises a Bigger Question About How Far the Rally Can RunMarketBeat Week in Review – 09/28 - 10/02Could Nike’s Brutal Sell-Off Finally Be Running Out of Steam?Time to Nibble on MCD Stock After it Enters Oversold Territory?Liberty Energy’s AI Power Push Has Wall Street Divided Upcoming Earnings PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
